Pfizer scores FDA pediatric expansion for hemophilia treatment Hympavzi

The FDA has expanded the label for Pfizer’s subcutaneous hemop | The FDA has expanded the label for Pfizer’s Hympavzi, now including patients age 6 and older who have hemophilia A or B. The new expansion covers all patients 6 and older, regardless of their inhibitor status. The new nod also opens up the treatment to those 12 and older who have developed inhibitors.